Yizhuo Zhao

Effect of Anlotinib as a Third-Line or Further Treatment on Overall Survival of Patients With Advanced Non–Small Cell Lung Cancer

Baohui Han, Kai Li, Qiming Wang et al. · JAMA Oncology · 2018 · 591 citations · Full text

Genomic Landscape Survey Identifies SRSF1 as a Key Oncodriver in Small Cell Lung Cancer

Liyan Jiang, Jiaqi Huang, Brandon W. Higgs et al. · PLoS Genetics · 2016 · 265 citations · Full text

Engineering, Pathology, Key Oncodriver +17

Anlotinib as a third-line therapy in patients with refractory advanced non-small-cell lung cancer: a multicentre, randomised phase II trial (ALTER0302)

Baohui Han, Kai Li, Yizhuo Zhao et al. · British Journal of Cancer · 2018 · 260 citations · Full text

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy of Paclitaxel-Carboplatin Alone or with Endostar for Advanced Non-small Cell Lung Cancer

Baohui Han, Qingyu Xiu, Huimin Wang et al. · Journal of Thoracic Oncology · 2011 · 89 citations

Oncology, Paclitaxel-carboplatin Alone, Medicine +6

Use of capture-based next-generation sequencing to detect ALK fusion in plasma cell-free DNA of patients with non-small-cell lung cancer

Shaohua Cui, Wei Zhang, Liwen Xiong et al. · Oncotarget · 2016 · 75 citations · Full text

Alk Fusion, Capture-based Next-generation Sequencing, Plasma Cell-free Dna +14